We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $8.34B
1-Year Est. Return 165.53%
This Fund
S&P 500
This Quarter Est. Return
+77.9%
1 Year Est. Return
+165.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$8.34B
AUM Growth
+$2.35B
Cap. Flow
-$42M
Cap. Flow %
-0.5%
Top 10 Hldgs %
46.57%
Holding
644
New
20
Increased
132
Reduced
424
Closed
57

Top Buys

Rank Stock Value
1
INIO
INNIO N.V.
INIO
+$177M
2
AMD icon
Advanced Micro Devices
AMD
+$119M
3
FORM icon
FormFactor
FORM
+$101M
4
CBRS
Cerebras Systems
CBRS
+$70.1M
5
ONTO icon
Onto Innovation
ONTO
+$64.5M

Top Sells

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$220M
2
LITE icon
Lumentum
LITE
+$219M
3
TSLA icon
Tesla
TSLA
+$50.1M
4
CIEN icon
Ciena
CIEN
+$43.3M
5
MSFT icon
Microsoft
MSFT
+$42.6M

Sector Composition

Rank Sector Weight
1 Technology 66.11%
2 Communication Services 9.64%
3 Consumer Discretionary 8.42%
4 Industrials 4.35%
5 Healthcare 4.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
526
Prothena Corp
PRTA
$504M
$11.2K ﹤0.01%
1,141
-58
-5% -$573
CBL
527
CBL Properties
CBL
$1.7B
$11.1K ﹤0.01%
210
-31
-13% -$1.44K
WSR
528
DELISTED
Whitestone REIT
WSR
$11.1K ﹤0.01%
587
-117
-17% -$2.2K
BRK.B icon
529
Berkshire Hathaway Class B
BRK.B
$1.08T
$11K ﹤0.01%
22
-146
-87% -$70.2K
KYTX icon
530
Kyverna Therapeutics
KYTX
$510M
$10.8K ﹤0.01%
1,212
+235
+24% +$2.09K
AQST icon
531
Aquestive Therapeutics
AQST
$670M
$10.7K ﹤0.01%
2,583
-144
-5% -$606
PACB icon
532
Pacific Biosciences
PACB
$420M
$10.7K ﹤0.01%
6,391
-314
-5% -$457
SLN
533
Silence Therapeutics
SLN
$907M
$10.7K ﹤0.01%
975
-72
-7% -$507
CTNM
534
Contineum Therapeutics
CTNM
$628M
$10.6K ﹤0.01%
647
+134
+26% +$1.76K
NGNE icon
535
Neurogene
NGNE
$772M
$10.4K ﹤0.01%
332
-8
-2% -$220
ESRT icon
536
Empire State Realty Trust
ESRT
$786M
$10.3K ﹤0.01%
1,906
-286
-13% -$1.55K
CABA icon
537
Cabaletta Bio
CABA
$588M
$10K ﹤0.01%
3,223
+1,074
+50% +$3.53K
SAFE
538
Safehold
SAFE
$1.07B
$9.94K ﹤0.01%
633
-82
-11% -$1.24K
EDIT icon
539
Editas Medicine
EDIT
$496M
$9.83K ﹤0.01%
3,033
+859
+40% +$2.51K
LKFT
540
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.87B
$9.5K ﹤0.01%
317
-1
-0.3% -$28
CCCC icon
541
C4 Therapeutics
CCCC
$463M
$9.4K ﹤0.01%
2,012
-153
-7% -$523
ALX
542
Alexander's
ALX
$1.34B
$9.37K ﹤0.01%
34
-1
-3% -$250
SGMT icon
543
Sagimet Biosciences
SGMT
$680M
$9.35K ﹤0.01%
1,210
+521
+76% +$3.54K
EOLS icon
544
Evolus
EOLS
$614M
$9.34K ﹤0.01%
1,346
-101
-7% -$596
ENTA icon
545
Enanta Pharmaceuticals
ENTA
$410M
$9K ﹤0.01%
617
-23
-4% -$309
KMDA icon
546
Kamada
KMDA
$493M
$8.98K ﹤0.01%
1,223
-65
-5% -$513
PBYI icon
547
Puma Biotechnology
PBYI
$493M
$8.76K ﹤0.01%
1,080
-42
-4% -$308
GOOD
548
Gladstone Commercial Corp
GOOD
$635M
$8.08K ﹤0.01%
657
-54
-8% -$673
UPB
549
Upstream Bio Inc
UPB
$329M
$7.92K ﹤0.01%
1,145
-58
-5% -$486
RCKT icon
550
Rocket Pharmaceuticals
RCKT
$424M
$7.87K ﹤0.01%
2,300
-114
-5% -$379
20 21
22
23 24

Similar funds

GLF
Groupe la Francaise Paris, France $8.31B AUM 37.53% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $8.31B AUM 21.94% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
MAM
Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
MWM
Modern Wealth Management Lenexa, Kansas $8.4B AUM 21.02% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $8.4B AUM 51.89% 1-Year Est. Return
OCA
OpenArc Corporate Advisory Atlanta, Georgia $8.41B AUM

GF Fund Management's Q2 2026 Portfolio in Review

As of Q2 2026, GF Fund Management held 644 positions worth $8.34B, up 39% from $5.98B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

GF Fund Management's Q2 2026 filing shows 20 new, 132 increased, 424 reduced and 57 closed positions. Its largest new stake was INNIO N.V.: 4,970,000 shares worth $197M. The largest sale was Tower Semiconductor, an estimated $220M.

By sector, the portfolio is most concentrated in Technology at 66% of assets, up from 54% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q2 2026 buy was INNIO N.V.: 4,970,000 shares worth $197M.
  • GF Fund Management added most to Advanced Micro Devices in Q2 2026, an estimated $119M increase.
  • GF Fund Management's biggest Q2 2026 reduction was Tower Semiconductor, cutting an estimated $220M.
  • GF Fund Management fully exited Coherent in Q2 2026, selling an estimated $23.3M.
  • GF Fund Management's ten largest holdings make up 47% of its $8.34B portfolio in Q2 2026.
  • GF Fund Management opened 20 new positions and closed 57 in Q2 2026.
  • GF Fund Management's portfolio value rose 39% quarter-over-quarter to $8.34B.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.